Background-This study explores health provider and patient attitudes toward the use of a cardiovascular polypill as a health service strategy to improve cardiovascular prevention. Methods and Results-In-depth, semistructured interviews (n=94) were conducted with health providers and patients from Australian general practice, Aboriginal community-controlled and government-run Indigenous Health Services participating in a pragmatic randomized controlled trial evaluating a polypill-based strategy for high-risk primary and secondary cardiovascular disease prevention. Interview topics included polypill strategy acceptability, factors affecting adherence, and trial implementation. Transcribed interview data were analyzed thematically and interpretively. Polypill patients commented frequently on cost-savings, ease, and convenience of a daily-dosing pill. Most providers considered a polypill strategy to facilitate improved patient medication use. Indigenous Health Services providers and indigenous patients thought the strategy acceptable and beneficial for indigenous patients given the high disease burden. Providers noted the inflexibility of the fixed dose regimen, with dosages sometimes inappropriate for patients with complex management considerations. Future polypill formulations with varied strengths and classes of medications may overcome this barrier. Many providers suggested the polypill strategy, in its current formulations, might be more suited to high-risk primary prevention patients. Conclusions-The polypill strategy was generally acceptable to patients and providers in cardiovascular prevention.
C ardiovascular disease is a major cause of mortality and morbidity worldwide and is projected to be the leading cause of death in 2030. 1, 2 A major part of the problem is large treatment gaps globally-for instance, audits of primary healthcare in Australia indicated that prescription of guidelines-recommended therapy is as low as 50%. 3, 4 Nonadherence to the treatment is likely to further extend this treatment gap because it is estimated that ≤50% of patients in highincome countries do not adhere to prescribed cardiovascular disease (CVD) medications, with similar suboptimal adherence in low-and middle-income countries. 5, 6 The reasons for nonadherence fit into well-recognized categories-health system, condition, patient, therapy, and socioeconomic. 7, 8 A review of strategies targeting CVD medication nonadherence in disadvantaged populations found that interventions directed at patients and providers simultaneously showed statistically significant improvements in relative adherence. 6 Cardiovascular polypills which are fixed-dose combinations of frequently indicated cardiovascular medications for highrisk primary prevention and secondary prevention have been trialled internationally to improve provider prescribing and patient medication use. Encouragingly, recent results from randomized controlled trials have shown effectiveness in improving adherence. [9] [10] [11] However, whether this promising result is generalizable and can be successfully implemented in health services outside of trial settings depends partly on whether the polypill strategy will be well received by health providers and importantly to patients. This can be addressed by qualitative research conducted alongside trials exploring relevant stakeholders' perspectives. [12] [13] [14] The Realist framework has been successfully used in process evaluations as a theoretical basis for identifying potential causal mechanisms of how an intervention works for whom, under what contexts, and thus fosters uptake of research-based knowledge into practice. [15] [16] [17] [18] [19] In this article, we present the qualitative findings of a process evaluation set within a multicenter pragmatic randomized, controlled trial (PRCT) of a cardiovascular-based polypill strategy in Australian primary care known as the Kanyini Guidelines Adherence with the Polypill (KGAP) trial. 1, 9 Patients received a fixed-dose combination containing aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, and either atenolol 50 mg or hydrochlorothiazide 12.5 mg in the polypill group. The usual care group continued cardiovascular preventive treatment, with separate medications and doses prescribed at their treating doctor's discretion.
This pragmatic trial was conducted in a variety of primary healthcare services across Australia in urban, rural, and remote settings, thereby maximizing potential generalizability 20 and sought to improve patient medication use and the prescribing of indicated therapy for high-risk primary and secondary CVD prevention patients. Significantly, in Australia where indigenous patients have a higher burden of CVD, 21 the trial was conducted in accessible and culturally safe indigenous health services (IHS). 22, 23 Primary outcomes were measured by self-reported medication use and changes in biological markers of changes in systolic blood pressure and total cholesterol. Results showed that "After a median of 18 months, the polypill-based strategy was associated with greater use of combination treatment (70% versus 47%; relative risk 1.49; 95% confidence interval [CI] 1.30-1.72; P<0.0001; number needed to treat=4.4 [3.3-6.6]) without differences in systolic blood pressure (−1.5 mm Hg [95% CI −4.0 to 1.0]; P=0.24) or total cholesterol (0.08 mmol/L [95% CI −0.06 to 0.22]; P=0. 26) . At study end, 17% and 67% of participants in polypill and usual care groups, respectively, were taking atorvastatin or rosuvastatin." (ANZCTRN 12608000583347) 10 We aim to explore the relevance of the polypill strategy for health providers and patients as a health service strategy to improve prescribing of indicated therapy and improve patient medication use. 24 Understanding the mechanism of the polypill strategy from patients and providers perspectives will assist in translation of the polypill intervention to other contexts and so inform policy and practice in the area.
Methods
A predefined protocol for the overall process evaluation was used and had been published. 24 Our methods are presented across key areas for reporting in qualitative research. 25 
Research Team and Reflexivity
Study investigators involved in the design and implementation of KGAP developed the process evaluation protocol and interview guides. The interviews were conducted by a team of 7 researchers who varied in qualitative research experience and had diverse backgrounds (nursing, health economics, pharmacy, Indigenous health). Three were indigenous and 4 were nonindigenous researchers. Two of the interviewers were research coordinators and had existing relationships with several of the participants interviewed, but the other interviewers were not known to the participants before the interviews.
Study Design
Participants were recruited purposively based on maximum variation of specified variables, which could potentially affect participants' views of a polypill-based strategy and with trial implementation. A sampling matrix was used with the following characteristics: for patients, these were location, age, sex, ethnicity, primary versus secondary CVD, and self-reported adherence at baseline; and for providers, location and profession. 26 All health providers and patients were approached by a letter of invite detailing the study and purpose and a follow-up phone call by the project coordinator. All health providers approached agreed to participate, though 5 patients declined to be interviewed and 2 patients were unavailable. Written informed consent was obtained.
The interview guides covered the key domains about the polypill strategy in CVD management, patient satisfaction or problems with the polypill, issues regarding trial implementation, and
WHAT IS KNOWN
• Although effectiveness trials have shown a significant improvement in patient medication use with a specific polypill formulation (a combination of a statin, 2 blood pressure lowering agents, and antiplatelet agent) when compared with usual care for high-risk primary and secondary CVD prevention, patients' and providers' perspectives of this approach are unknown.
WHAT THE STUDY ADDS
• After conducting qualitative interviews with both providers and patients involved in a pragmatic clinical trial in Australia, we found general acceptability of the polypill-based strategy with patients reporting greater convenience and cost savings with the polypill. • However, some prescribers highlighted limitations of this particular formulation in regards to dosage inflexibility and recommended that more doage combinations be made available.
translation of the polypill into clinical practice. Interview guides were iteratively revised to explore themes and issues emerging from earlier interviews. Interview guides are available as Data Supplements. Ninety-four semistructured interviews were conducted at the end of KGAP with 47 providers (25 general practitioners [GPs], 13 pharmacists, 6 Aboriginal Health Workers, and 3 Chronic Care Nurses) and 47 patients in New South Wales, Queensland, and Victoria. Twenty-two and 25 patients were in the polypill arm and usual care arm, respectively. Twenty-one and 26 patients were in the primary and secondary prevention arm, respectively. There were 28 nonindigenous patients and 19 indigenous patients. Participant characteristics are included in Table in the Data Supplement. Most interviews (ranging from 30 minutes to an hour) were conducted face to face either at home or at the health service and audiorecorded. Two interstate participants were unavailable at a time that coincided with travel to their health services. It was not feasible to schedule an additional visit because of time, interviewer availability, and cost. Instead, these 2 interviews were conducted by phone and audio-recorded. To ensure consistency, one researcher (L. Massi) was involved in most of the interviews. She conducted 42 alone and another 40 with another researcher. 26 L. Massi was trained in qualitative research methods and coordinated the study. Preliminary thematic data analysis was conducted by L. Massi alongside the interviews and discussed with the research team. Thematic saturation was reached, and further interviews were conducted to ensure that we had gleaned perspectives from the different regions.
Analysis
Interviews were professionally transcribed and coded by 2 researchers (H. Liu and L. Massi) using NVivo 9 (QSR International, Melbourne, VIC) at the completion of the interviews. Using the constant comparative method, 14 these researchers coded the same 12 transcripts independently through 3 iterative stages and developed an initial coding framework encompassing both patients' and providers' perspectives, allowing triangulation of findings within each code. Insights gained by the KGAP research team about the local setting and empirical results of the PRCTs were used to aid interpretation. 27, 28 The coding framework was refined with input from study investigators and interview team. This included 2 IHSs clinicians who were site principal investigators and provided respondent validation. 27 H. Liu and L. Massi coded the remaining interviews equally, drawing up memos for each interview to provide additional context for others analyzing the data and recoded the original 12 interviews. Minor, iterative changes to code definitions were made. An audit trail was kept. For this article, all data assigned to codes relating to the polypill strategy in CVD management were analyzed by H. Liu and the Realist framework of context-mechanism-outcomes utilized to develop the themes 15, 16 (see Figure) . Further description of the major codes and the coding framework are available as Data Supplements. The study was approved by 7 regional ethics committees.
Results
Three principle themes relating to the polypill as a health service strategy to improve CVD prevention in Australian primary care were derived (Table in the Data Supplement is available with additional quotes).
Overall Acceptability of the Polypill Strategy

Ease and Convenience
A key strength described by many patients and providers was that overall the polypill was liked and perceived as a beneficial strategy because of the ease and convenience of a single daily-dosing capsule. It was physically easier to take and to remember to take, which was highlighted by some providers and patients as especially important for the elderly and for those with stressful and competing life priorities. A few providers assumed that the polypill would increase adherence because long-term adherence to preventative medication was challenging for their patients. An indigenous patient described how the polypill reduced her psychological pill burden:
… taking so many individual tablets became stressful, it's like you knew what was happening like this organ and that organ is not working but with the polypill, because it's all in one and you're not having these different things laid out before your eyes. It was easy. (Patient 31, remote IHS)
Codes and themes within the realist framework (context-mechanismoutcome). CVD indicates cardiovascular disease. May 2015
Cost Savings
The polypill strategy was a pragmatic trial, which aimed to mimic real-world cost impacts on participants. In the Australian context, where medications could be subsidized through the Pharmaceutical Benefits Scheme (PBS), nonconcession card holders would pay full copayments for prescriptions (≈$AUD30), whereas concession card holders would pay subsidized copayments of $AUD5.60 for each prescription. For these groups, there was a potential 4-fold cost advantage of the polypill. For indigenous participants who were eligible for complete medication subsidization through a government scheme newly introduced during the PRCT, there was no cost advantage of the polypill because treatment in both arms was subsequently free. Thus, depending on individual circumstance, the savings varied for the patients. Most of the providers recognized that the polypill would help improve their patients' adherence to CVD medications because of ease, convenience, and cost-savings of the polypill. A GP described the advantages of the polypill for his patients and in starting medications:
Taking one pill instead of four is excellent and improves compliance with patients; there is a cost factor that is an advantage. There is a simplicity factorit's easier to start someone early on, on a four-medication thing if they need it. If someone sort of never comes in and is poorly compliant and for months or years they've sort of had little warning signs that they really need something done but they don't really do it, the polypill does make it possible to fairly easily say, 'let's take this pill instead of this pill, it's just that this pill contains four medications.' (GP 27, urban IHS) The perceived advantages of the strategy as described by many of the providers may explain the difference in the prescription of antiplatelet, statin, and at least 2 blood pressure lowering agents which at baseline percentage was 50% and increased to 79% in the polypill arm and only 52% in the usual care arm.
Adherence Depends on Other Factors
However, despite many patients describing how and why the polypill could improve medication use, other factors were also described by the patients as being key to their adherence. Patients indicated that their adherence behavior was determined by intrinsic factors, such as establishing routine medication regimens, their sense of well-being, and their understanding of medications, aided by external factors, such as the perceived quality and accessibility of their healthcare, family, and community support, respectful patient-provider relationships, and financial assistance from the government. Examples of quotes illustrating these factors include: Patients also described initiatives, such as having dose administration pack, removed the hassle of carrying many medications, and served as a reminder to take their medications.
Similarly, many providers perceived intrinsic and extrinsic factors affected their patients' medication use.
It's very hard, we've done motivational training [in regards to adherence] and the Division [of GP's]
has tried all sorts of things to help these people and they're just not interested. They have lives often with so many complexities which they can't manage. (GP 36, regional GP clinic) Clearly the evidence around the world is that the primary care practitioner/patient relationship is the magic ingredient in the health system. There's continuity and there's trust. You get better outcomes and part of that is that people are more willing to commit to treatment plans. I think the General Practitioner's role is key in promoting adherence. (GP 1, rural GP clinic)
Many providers indicated that the perceived potential impact of the polypill strategy in improving their patients' medication use depended on existing adherence behavior. For example, though pharmacist 42 (remote IHS-related pharmacy) talked about how if pill burden was a key barrier then the polypill would be ideal, another pharmacist described a limited impact of the polypill strategy if patients were already adherent and used dose administration devices: 
Polypill Strategy in Patient Management
Limitations of a Fixed Dose Combination
Some providers described certain limitations of the polypill strategy in patient management. They commented on the inflexibility of a fixed dose combination and on the complexity in identifying which component of the polypill caused any reported side effect.
I think the Polypill is a good idea in principle but it also showed me how complicated it is to give somebody a pill with four components. One of the biggest parts of my work is dealing with adverse drug reactions and if you give a person one medication there's a pretty good chance they're going to get an adverse reaction. Now it may be a minor one, may not be, if you give them four, that's a lot more chances. And then teasing out which one is difficult. (GP 10, urban GP clinic)
At some sites, providers described patients on the trial with complex medical problems that in hindsight were not sufficiently stable for the polypill.
I was surprised with some of the patients whom others had been happy to put on it because when we looked at the problems that some [patients] had, I thought, well I wouldn't have put that person in the trial, in the first place [because]
) they were quite complicated and there will be potential risks of having some problems on the polypill. (GP 36, regional GP clinic) Some providers found that the polypill formulations used in the trial contained inadequate dosages for their patients, expressing an inclination to discontinue its use if additional medications were needed because the advantage of a one daily-dosing pill was lost.
Adequacy of the Polypill Components
The therapeutic efficacy of the generic components within the polypill was discussed by many of the providers. There were 2 perspectives: some GPs questioned whether these particular polypill formulations would represent best practice, given the perceived superiority of some of the newer on-patent medications available. Conversely, some providers preferred the use of off-patent medications contained in the polypill because of the cost-savings and the greater evidence-base of these older medications. A GP gave the following opinion of the on-patent medications compared with the older generics:
So much of the PBS is bound up with cardiovascular management. I have a personal belief that we spend far too much on the PBS. There are far too many medications that are not generic and we seem to want to have the most expensive and I personally don't believe in that. I think people are prepared to live their lives as they wish and [some] smoke and drink. We do our best and we assume that the medication is, a hundred per cent, is all the treatment, which it's not. So I don't believe they have to have Rolls Royce medications when they lead a beat up Hyundai Lifestyle. What they need is to actually take the medications regularly, understand what they're for... I'd much rather go with a lot more evidence-based cheaper medications and getting people to take them. (GP 39, remote IHS) Some GPs also expressed an uncertainty about the individual components. Several providers were uncertain about the use of aspirin for nondiabetic patients without established CVD. Some of the GPs and the patients' cardiologists preferred to prescribe the newer statins if possible. This was also reflected in the PRCT's data, which showed that at the end of the study, 17% and 67% of participants in polypill and usual care groups, respectively, were taking atorvastatin or rosuvastatin.
I think that there was one local cardiologist who wasn't at all supportive of the polypill …. And this particular cardiologist also tended to use the top end dose of statins when he'd seen a patient, so that had the potential to raise an issue for a patient who we would then have to prescribe polypill plus an additional statin to keep them on the same dose as the cardiologist… I'm not actually convinced that the patients all needed to be on that dose. (GP 25, urban IHS)
These providers' perspectives about limitations of a fixed dose combination and questions regarding the adequacy of the polypill components offer possible explanations of why 28% of patients who were randomized to the polypill stopped it at some stage with around half of these discontinuations being because of prescribing and, thus apparently, were provider-initiated.
Future Combinations Would be Beneficial
Many providers and patients believed the above mentioned limitations could be overcome by having other polypills with different drug combinations. Some providers also stated a combination pill could be formulated for other diseases like diabetes mellitus, as in the following quote:
Once the general principle of a cardiac medication that's polyvalent is established then there ought to be some flexibility as to what components might be added, with the advantage of future research. (GP 23, urban IHS)
Who Could it be Suitable for?
High-Risk Primary Prevention Patients
Many providers were of the belief that the polypill formulations used in the study were inappropriate for some secondary prevention patients because of the low and inflexible dosing. Rather, its niche was in high-risk primary prevention patients who were stable medically.
Using a generalised polypill with lower doses where you have a person who hasn't got the cardiovascular disease but has cardiovascular risk would be good just to help them from developing full-on cardiovascular disease. I think there's a role there -where there might be the one blood pressure tablet … because they might have had minor hypertension and putting a statin in there with aspirin just keeps everything functioning well and stops them getting established May 2015 cardiovascular disease. Whether it's got a role in the patient who already has cardiovascular disease, I'm not sure because you can't alternate the doses the way you want. (Pharmacist 7, urban IHS) This theme supports the trial finding of the polypill-based strategy, resulting in a proportionately greater improvement in combination treatment use among high-risk primary prevention patients, though this improvement was also significant in patients with established disease.
Strategy to Address CVD Burden in Indigenous Patients
Although the acceptability of the polypill strategy on improving adherence was reported by both patients and providers in IHSs and private clinics, a strong finding was that there could be particular advantages for indigenous patients. A GP thought the polypill could be an effective strategy to reduce the CVD burden in his community:
Being an Aboriginal doctor I see the burden of disease especially in cardiovascular health…. The youngest fellow we've had coming in here is 28 having a heart attack. So we see heart disease early and it's not uncommon for some of our patients to have heart attacks in their 30s, 40s and 50s. So I think we need some other strategy to help decrease that risk and that's where I've seen the place for the polypill and it'd be interesting to see what results come out of it. ( GP 28, urban IHS) A GP (Provider 43, remote IHS) described the usually lengthy process of starting medications in indigenous patients and how the polypill could be used to expedite this process. Moreover, by not having a pharmacist provide medications in a medication dose aid might mean increased ownership of health for his patients on the polypill. An indigenous patient thought the polypill would be a way to bridge the health literacy gap:
It would be a good thing … for a lot of our people … if they've got to take about half a dozen tablets or four tablets you know they might get confused. Some of our people you can't read much to know what tablets to take. They just take them...
[They] don't know what they're taking it for. I reckon it's a good idea if they've got the polypill [which] is all in the one. (Indigenous patient 43, remote IHS)
Several GPs at some IHSs thought the polypill strategy complemented their services' chronic disease model of care, updated them on their CVD guidelines, and encouraged them to use the CVD absolute risk calculation in their patient management. Provider 20 (pharmacist, urban IHS) thought the polypill strategy worked synergistically with the GP's education of patients and the pharmacists' provision of the dose administration aid to improve patients' adherence.
It seemed that the polypill strategy could potentially be beneficial for the indigenous population, given the high disease burden and the complexities associated with taking multiple medications. It was viewed as an acceptable strategy by patients and providers for high-risk, medically stable patients. Many IHS providers thought the polypill strategy could be an effective component of CVD care that could be integrated into strategies that address other factors, such as accessible care, health promotion, and social determinants. Indeed, the PRCT subgroup analysis showed that there was a significant improvement in medication use among the indigenous patients randomized to the polypill strategy.
Discussion
The polypill strategy is relevant to patients' and providers' needs as an acceptable health service strategy to improve CVD prevention in Australian primary healthcare. Using the Realist framework, the effectiveness of the polypill strategy was dependent on whether the health provider felt that the polypill components were adequate for the management of individual patients' CVD, and would encourage patient's adherence because of its ease and convenience, and cost savings for the patient. However, the sustainability and impact of the polypill strategy in improving adherence depended on other patient factors, such as affordability of medications, level of health literacy, compatibility with existing adherence strategies, sense of well-being, patient-provider relationship, access to quality care, and disease stability and severity. The main limitation of the strategy was the inflexibility in dosing, but this was viewed as a shortcoming that could be addressed with introduction of a wider range of combinations. In its current formulations, many of the providers in this study deemed it to be particularly suited to high-risk primary prevention patients and some indigenous populations in Australia.
Our study confirms some findings of other qualitative studies which showed a growing acceptance of prescribing the polypill for primary and secondary prevention, provided there is evidence of effectiveness and cost benefits. [29] [30] [31] However, our study also highlighted overall patient acceptability of the polypill strategy and a key recommendation by providers to improve the flexibility of the polypill strategy in meeting the varied needs of patients by introducing more formulations. Using qualitative research alongside a PRCT enabled us to better appreciate the role of the polypill strategy in addressing inequity within contextual factors of Australian primary healthcare, such as high CVD burden within indigenous communities, existing costs of medications, and concurrent government policies for medication subsidies.
This study was limited in that it was an in-depth exploration of issues from a sample that was not necessarily representative of all participants and providers in the trial. Fewer interviews were done in remote sites, and staff who had left the service or participants who had withdrawn by the end of the study would not have been interviewed. Other limitations of our study include having 2 interviews done over the phone in comparison to face to face, varying level of experience of qualitative research among the study team and achieving only partial member checking during a presentation of preliminary findings to a subset of providers.
Though the KGAP trial showed that there was improved adherence in the polypill arm, patients' adherence in both arms of the study progressively declined over time, which is consistent with the literature. [32] [33] [34] Thus, the question remains as to how to best use the polypill strategy to improve sustained medication adherence. A method to characterize behavior change interventions was proposed by Michie et al through the use of a behavior change wheel, which comprises a behavior system at the hub, encircled by 9 intervention functions aimed at addressing the deficits in capability, motivation, and opportunity and then by 7 policy categories to enable the interventions to occur. 35 Applying Michie's behavior change wheel to our results, it seems that the polypill strategy has the intervention functions of enablement and incentivization; to effect behavior change, but perhaps other intervention strategies and policies are needed for sustained change. Multifaceted approaches to improve adherence have been trialled internationally. 8, 36, 37 In Australian primary health care, a quality improvement intervention with pharmacists-led education to improve health literacy and electronic decision support for the prescribing of preventative medications has been shown to be effective. 36 Our study findings suggest that the polypill strategy could potentially be used successfully and synergistically with similar health service strategies to improve medication persistence in this setting.
The polypill strategy is increasingly being recognized as a part of a solution for improving global CVD prevention, with a growing body of evidence showing effectiveness in improving provider prescribing and patient adherence to indicated CVD medications. 10, 11, 38, 39 The economic evaluation conducted with the KGAP trial 40 and a cost-effectiveness study of a multidrug regimen (similar to the polypill components) in a lower middle income setting 41 provide promising evidence that the polypill strategy could reduce the high global economic burden of CVD, given the availability of the inexpensive yet effective drugs. As more CVD medications come off patent, our findings imply a key challenge would be to have different polypill versions made available as an affordable and attractive health service strategy for both high-income and lower middleincome countries. However, barriers to the implementation of the polypill strategy include the manufacture of the polypill as a viable business for pharmaceutical companies, despite its huge public health potential and having supportive legislation and policy changes. As such, the amalgamation of evidence from international trials combined with further research in cost effectiveness and acceptability of the strategy in different contexts will determine the feasibility and policy significance of the polypill strategy in improving CVD prevention worldwide.
